Page last updated: 2024-11-12

(2s,3as,7as)-1-(((r,r)-2-phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1h-indole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S 17092-1: structure in first source; inhibits proline endopeptidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9929984
CHEMBL ID1086968
SCHEMBL ID194654
MeSH IDM0487253

Synonyms (24)

Synonym
cid 9929984
CHEMBL1086968 ,
((2s,3as,7as)-1-((1r,2r)-2-phenylcyclopropanecarbonyl)octahydro-1h-indol-2-yl)(thiazolidin-3-yl)methanone
bdbm50316818
s-17092
176797-26-5
s 17092
[(2s,3as,7as)-octahydro-1-[[(1r,2r)-2-phenylcyclopropyl]carbonyl]-1h-indol-2-yl]-3-thiazolidinyl--methanone
S17092 ,
[(2s,3as,7as)-2-(1,3-thiazolidine-3-carbonyl)-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-[(1r,2r)-2-phenylcyclopropyl]methanone
gtpl6565
SCHEMBL194654
DTXSID70433003
s 17092, >=98% (hplc)
NCGC00485216-01
Q27088661
unii-8w5mlj83ku
s 17092-1
((2r,3ar,7as)-2-(1,3-thiazolidin-3-ylcarbonyl)-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl)-((1s,2s)-2-phenylcyclopropyl)methanone
8W5MLJ83KU ,
F82023
MS-26334
HY-15114
CS-0003770

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The terminal half-life (t(1/2)) values ranged between 9 and 31 h on day 1 and between 7 and 18 h on day 14."( Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
De Nanteuil, G; Guez, D; Heidet, V; Jochemsen, R; Morain, P; Robin, JL, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The results obtained in elderly healthy subjects indicated that S 17092 is suitable for once-daily dosing without any serious adverse events."( Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
De Nanteuil, G; Guez, D; Heidet, V; Jochemsen, R; Morain, P; Robin, JL, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prolyl endopeptidaseRattus norvegicus (Norway rat)Ki0.00130.00000.10840.6300AID481394
Prolyl endopeptidaseHomo sapiens (human)IC50 (µMol)0.00200.00111.98969.7500AID341663
Prolyl endopeptidaseHomo sapiens (human)Ki0.00150.00000.00200.0080AID1307744; AID481402
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
proteolysisProlyl endopeptidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityProlyl endopeptidaseHomo sapiens (human)
protein bindingProlyl endopeptidaseHomo sapiens (human)
serine-type peptidase activityProlyl endopeptidaseHomo sapiens (human)
oligopeptidase activityProlyl endopeptidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusProlyl endopeptidaseHomo sapiens (human)
cytoplasmProlyl endopeptidaseHomo sapiens (human)
cytosolProlyl endopeptidaseHomo sapiens (human)
membraneProlyl endopeptidaseHomo sapiens (human)
cytosolProlyl endopeptidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1896133Inhibition of POP (unknown origin)2022European journal of medicinal chemistry, Oct-05, Volume: 240Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-α for different indications.
AID341663Inhibition of human recombinant POP expressed in sEscherichia coli2008Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15
Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
AID481394inhibition of rat cortex POP2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors.
AID1307744Inhibition of human POP using Z-Gly-Pro-7-AMC substrate2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors.
AID481402Inhibition of human POP2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors.
AID1345978Human prolyl endopeptidase (S9: Prolyl oligopeptidase)2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.76)18.2507
2000's10 (47.62)29.6817
2010's7 (33.33)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.59 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (9.09%)5.53%
Reviews2 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]